Curative Effect Observation of Lienal Polypeptide Injection for Patients with Mutation Negative Advanced Non-Small Cell Lung Cancer with Immune Combination Chemotherapy
Objective To analyze the effect of lienal polypeptide injection combined with carizolizumab and chemotherapy on the immune function and effect of patients with advanced lung adenocarcinoma. Methods The paper included 50 patients with advanced lung adenocarcinoma in Heilongjiang Provincial the Fourth Hospital from January 2023 to October 2023 for study,and divided them into the control group (with chemotherapy treatment) and the observation group (with lienal polypeptide injection combined with carilizumab+chemotherapy) randomly,with 25 cases in each group. All cases were treated continuously for 4 coures,and clinical treatment effect was compared between different treatment modes. Results Comparison of immune function indicators between groups showed,there was no statistical difference between the observation group and the control group before treatment (P>0.05). After 4 course of treatment,levels of CD3+,CD4+,CD4+/CD8+in the observation group were higher than the control group,and level of CD8+was lower than the control group,(P<0.05). Comparison of treatment effect showed,that of the observation group was higher than the control group (P<0.05). There was no significant difference in incidence of adverse reactions between the observation group and the control group,(P>0.05). Conclusion Lienal polypeptide injection combined with carilizumab+chemotherapy can improve clinical treatment effect and immune function of patients with advanced lung adenocarcinoma,with high drug safety and comprehensive application value,which is worthy of promotion in clinical practice.
万方数据
维普
